Rare and Atypical Diabetes Network

Recruiting now

Conditions studied: Diabetes Mellitus, Diabetes Mellitus Progression, Glucose Intolerance, Glucose Metabolism Disorders, Metabolic Disease, Endocrine; Complications, Endocrine System Diseases

In brief

RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes. The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to: 1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes. 2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes. 3. Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes.

Key facts

Study ID

NCT05544266

Run by

University of South Florida

People needed

2000

Starts

2020-09-30

Expected to finish

2030-09-01

Last updated by the study team

2025-08-14

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The following criteria or phenotypes will be considered for suspecting "atypical" participants:
• Type 2 diabetes diagnosed at a time when the individual was prepubertal or non-obese
• Mendelian pattern, especially with early onset (<18 years old)
• Syndromic (multiple systems involved)
• Lipodystrophic
• Extremes of BMI
• "Mitochondrial" characteristics (e.g., myopathy, hearing deficits)
• Non-progressive
• Rapidly progressive ("fulminant")
• Low insulin requirements (<0.5 u/kg/day)
• Cyclical hyperglycemia with periods of remission
• Lean persons with polycystic ovarian syndrome (PCOS)
• History of gestational diabetes (GDM) when lean
• Lean insulin-resistant persons
• If islet autoantibodies and beta-cell function parameters have been measured (where "A" = islet cell autoantibodies, "B" = beta-cell function):
• oA-B- (i.e., lacking islet autoimmunity makers and lacking beta cell function) oA-B+ with unprovoked DKA at initial presentation (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but presenting with unprovoked DKA) oA-B+ of very young onset (pre-pubertal) (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but very early onset T2D-like phenotype)

You may not qualify if…

• Those with high likelihood of typical type 1, typical type 2, known monogenic, or other known secondary forms of diabetes
• Refusal of consent for genetic testing
• Islet autoantibody positive (participants who are islet autoantibody positive but present with additional atypical features i.e. syndromic, strong linear family history of diabetes may not be excluded)
• Women who are currently pregnant

Where it is running

• University of Colorado- Denver — Aurora, Colorado, United States (enrolling)
• University of Chicago — Chicago, Illinois, United States (enrolling)
• Indiana University — Indianapolis, Indiana, United States (enrolling)
• University of Maryland — Baltimore, Maryland, United States (enrolling)
• Massachusetts General Hospital (MGH) — Boston, Massachusetts, United States (enrolling)
• University of Michigan — Ann Arbor, Michigan, United States (enrolling)
• Washington University in St. Louis — St Louis, Missouri, United States (enrolling)
• SUNY Downstate Health Sciences University — Brooklyn, New York, United States (enrolling)
• Columbia University — New York, New York, United States (enrolling)
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States (enrolling)
• Vanderbilt University — Nashville, Tennessee, United States (enrolling)
• Baylor College of Medicine — Houston, Texas, United States (enrolling)
• University of Washington — Seattle, Washington, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.